论文部分内容阅读
自70年代初利福平问世以来,迄今尚未找到新的重要的抗痨药。唯一例外的是丁胺卡那霉索偶可用于需服对氨基糖苷抗生素治疗的结核病人。丁胺卡那霉素对链霉素具有耐药的结核分棱杆菌菌株有作用,但丁胺卡那霉素与卡那霉素,卷须霉素两药间有交叉耐药。10年来,虽然生产新的抗分枝杆菌药物不多,但在改善结核病的化疗方面却有了重要进展。有些研究证实异烟肼与利福平联合用药可缩短总疗程,由常规疗程18～24个月缩短到9个月。如在异烟肼与利福平联合用药期的头2个月加用呲嗪酰胺或另一种药(通常加用链霉素或乙胺下醇),尚可将总疗程缩短至6
Since the advent of Rifampin in the early 1970s, so far no new and important anti-tuberculosis drugs have been found. The only exception is that the amikacin kyphosis can be used to treat tuberculosis patients who are taking aminoglycoside antibiotics. Amikacin has antibacterial effect on streptomycin-resistant strains of Mycobacterium tuberculosis, but there is cross-resistance between amikacin and kanamycin and curcumin. For 10 years, although few new anti-mycobacterial drugs have been produced, significant progress has been made in improving the chemotherapy of tuberculosis. Some studies confirmed that isoniazid and rifampicin combination therapy can shorten the total course of treatment, from the routine course of 18 to 24 months reduced to 9 months. If the combination of isoniazid and rifampin in the first two months plus otolazine amide or another drug (usually with streptomycin or ethylamine under alcohol), can still reduce the total duration of treatment to 6